Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + uliledlimab
- Development stage
- Phase 3
- Lead developer
- I-MAB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination involves **toripalimab**, a PD-1 antibody, and **uliledlimab**, a CD73 antibody. Toripalimab works by blocking the PD-1/PD-L1 interaction, enhancing the body's immune response against cancer cells. Uliledlimab targets CD73, an enzyme involved in adenosine production, which can suppress immune responses in the tumor microenvironment. By inhibiting CD73, uliledlimab aims to enhance anti-tumor immunity. The combination is being studied for its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC).
- Brand names
- TUOYI
02
Targets
NT5E (Cluster of Differentiation 73)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + uliledlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + uliledlimab.